Radiopharm Theranostics Limited (RADX) Stock

About Radiopharm Theranostics Limited

Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.

Radiopharm Theranostics Limited is headquartered in AU.

Radiopharm Theranostics Limited (RADX) stock trades at $0.98 with a market capitalization of $1.26M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.26, reflecting a net loss over the last twelve months, price-to-book of 0.57, price-to-sales of 3.42. Over the past 52 weeks the stock has ranged between $0.90 and $16.25, and currently trades 94.0% below its 52-week high.

On profitability, Radiopharm Theranostics Limited generates a return on equity (ROE) of -144.24% (negative, reflecting a net loss), return on capital employed of -170.88%, an operating margin of -2233.33%, a net profit margin of -1800.00%.

Official website: www.radiopharmtheranostics.com

Radiopharm Theranostics Limited (RADX) — frequently asked questions